MGI(688114)2024-06-06 07:36Group 1: Investor Relations Activities - The investor relations activity took place on June 4, 2024, with a total of 39 institutions and 45 participants [1] - The meeting included various formats such as analyst meetings, media interviews, and performance briefings [1] Group 2: Legislative and Market Concerns - The revised U.S. Biosecurity Act has been passed by the House Oversight and Accountability Committee, but final legislation is still pending [2] - The company noted that its business in the U.S. is minimal, with 2023 revenue from the U.S. and UK being relatively low [2] - The company is focused on localizing its brand in the U.S. market to alleviate customer concerns regarding supply stability and tariffs [2] Group 3: Domestic Market Opportunities - The domestic equipment update policy is expected to create new market opportunities for the company and other domestic medical device manufacturers [3] - The 2023 research market has seen significant growth in single-cell and spatial sequencing, gaining recognition from translational medicine researchers and pharmaceutical companies [3] Group 4: Sales and Revenue Insights - In 2023, the global sales of gene sequencers exceeded 4,500 units [4] - As of March 31, 2024, the company's order backlog was 745 million yuan, with gene sequencer business accounting for 75.7% [5] - The company generated 763,406,960.28 yuan (27%) of its main business revenue through distribution and 2,103,771,290.20 yuan (73%) through direct sales in 2023 [5] Group 5: Financial Performance and Projections - The first quarter of 2024 saw a slowdown in reagent revenue growth compared to the previous year, influenced by procurement cycles and project funding [4] - The company anticipates future growth in reagent revenue as clinical applications expand and research technologies continue to evolve [4] Group 6: Supply Chain Management - The company is actively enhancing its upstream supply chain management to mitigate risks associated with key raw materials [6] - Efforts are being made to establish domestic production capabilities for critical materials and to develop a regional supply chain for optical components [6]